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Background: The increase in relative biological effectiveness (RBE) of proton beams at the distal edge of the
spread out Bragg peak (SOBP) is a well-known phenomenon that is difficult to quantify accurately in vivo. For
purposes of treatment planning, disallowing the distal SOBP to fall within vulnerable tissues hampers sparing to the
extent possible with proton beam therapy (PBT). We propose the distal RBE uncertainty may be straightforwardly
mitigated with a technique we call “range modulation”. With range modulation, the distal falloff is smeared,
reducing both the dose and average RBE over the terminal few millimeters of the SOBP.
Methods: One patient plan was selected to serve as an example for direct comparison of image-guided
radiotherapy plans using non-range modulation PBT (NRMPBT), and range-modulation PBT (RMPBT). An additional
plan using RMPBT was created to represent a re-treatment scenario (RMPBTrt) using a vertex beam. Planning
statistics regarding dose, volume of the planning targets, and color images of the plans are shown.
Results: The three plans generated for this patient reveal that in all cases dosimetric and device manufacturing
advantages are able to be achieved using RMPBT. Organ at risk (OAR) doses to critical structures such as the
cochleae, optic apparatus, hypothalamus, and temporal lobes can be selectively spared using this method.
Concerns about the location of the RBE that did significantly impact beam selection and treatment planning no
longer have the same impact on the process, allowing these structures to be spared dose and subsequent
associated issues.
Conclusions: This present study has illustrated that RMPBT can improve OAR sparing while giving equivalent
coverage to target volumes relative to traditional PBT methods while avoiding the increased RBE at the end of the
beam. It has proven easy to design and implement and robust in our planning process. The method underscores
the need to optimize treatment plans in PBT for both traditional energy dose in gray (Gy) and biologic dose (RBE).
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Proton beam therapy (PBT) has emerged as an import-
ant advance in radiation therapy, particularly for
children and young adults. Although there are data sup-
porting equivalent rates of cure using equivalent doses
of proton versus photon treatments, the decreased dose
to nearby OARs and substantial reduction of irradiated
tissue volume is a promising strategy to address acute
and late injury to normal tissues from therapy [1]. Add-
itionally, a matched pair analysis [2] supports a range
from no difference to fewer second malignancies in pa-
tients treated with protons versus photon therapy. Simi-
lar data comparing photon CSI to proton CSI from
multiple institutions also suggests a clear correlation of
irradiated volume to risk of second malignancy [3-6].
Increased tissue effects at the end of the spread out Bragg
Peak (SOBP) is a defined, measured biologic phenomenon
[7-10]. The potential for unintentional tissue injury due to
putative increased relative biological effectiveness (RBE) at
the distal edge of a proton beam is an issue that must be
addressed during the planning process [8,11-13]. The exist-
ing models suggest there may be a 5-10% increase in bio-
logical effect at the most distal portion of the SOBP relative
to the plateau and an extension of effective proton range by
1–2 mm independent of fractionation and tissue type, while
noting “There are no proton RBE values based on human-
tissue response data, despite clinical experience of the treat-
ment of more than 50,000 patients”. [ICRU-78 [14]; Section
2.4] Current areas of research are exploring how the RBEFigure 1 The physical dose for a SOBP composed of four pristine Bra
illustrative model of increased distal RBE to the individual pristine peaks pro
the changes in SOBP plateau flatness, range, and effective dose at the dista
two parts and shifting one by 3 mm to both smooth out the SOBP and deof protons also varies with fraction size and how it affects
range [15,16].
In recognition of this dilemma, some current pediatric
treatment protocols mandate multi-beam proton plans
with the rationale that multiple beam entry directions
will reduce the dose to critical structures in close prox-
imity to the tumor. However, adding more beams may
be detrimental in some cases or may simply increase lo-
gistics without therapeutic benefit. An example is the re-
treatment of a brain tumor in which the brainstem, skin,
and surrounding tissues have already acquired a signifi-
cant dose from prior treatment. There may not be an
optimal beam entry direction, let alone multiple entry
directions in such cases. To address the issue of a poten-
tial increased RBE at the distal edge of a proton beam,
another approach chooses to stop the beam beyond, ra-
ther than in, the OAR in order to place the distal por-
tion of the SOBP in less vulnerable tissue downstream.
This requires acceptance of the OAR receiving full dose
uniformly as a safety measure in order to avoid a poten-
tially serious, but poorly quantifiable, complication.
Using mixtures of these methods, it is possible that
OARs would receive more dose than they would from
treatment with an alternative modality, such as IMRT.
Both of these strategies keep practitioners from using
proton technology optimally. Range modulation has
been deployed across a number of different tumor types
for various planning scenarios since August 2010 when
first developed. In order to make this comparison valid,gg peaks each separate by 6 mm water equivalent. Applying our
duces the RBE weighted SOBP. The “range mod” technique mitigates
l edge. Here the modulation is achieved by splitting the SOBP into
crease the RBE at the end of the beam.
Figure 2 Splitting the SOBP into three beams so as to further reduce the RBE effect. This what is typically done when a single beam plan
is being used such as with a posterior fossa boost or germinoma boost after whole ventricular radiation is employed. It can be employed at
other times as well when there is significant clinical concern regarding a specific organ at risk.
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structed to demonstrate the use of this new technique.
Methods
This manuscript describes a novel technique to mitigate is-
sues related to increased RBE at the distal edge of the SOBP
by spoiling the distal falloff with existing patient specificFigure 3 The plan using NRMPBT.device (PSD) sets and beam angles. We call this technique
“range modulation” or “range mod”. This is accomplished
by splitting the dose planned for a beam in half, shown in
Figure 1, and then delivering half the dose as planned and
other half of the dose with an identical beam whose range
has been modified by 3 mm [see reference on treatment
system ref [13], 3 mm is half the 6 mm spacing between
Figure 4 The plan using RMPBT as the primary treatment. DVH colors are the same as used in Figure 3.
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and comparable to the potential 1–2 mm increase in range
due to RBE). If a single beam is being used for a plan to a
significant dose, three beams are used and the range is
modified by 2 mm for each beam making the two beam
range changes 2 mm and 4 mm as shown in Figure 2. With
this technique, OARs are spared unnecessary dose. As an
example, we assumed the proton beam to have a uniform
RBE of 1.1 and modeled the excess RBE analytically with a
hyperbolic tangent centered on the point of maximum dose
of the pristine Bragg peak and saturating at 35% with a
characteristic length of 2 mm [8]. Applying this model to
the individual pristine peaks comprising the delivery of a
SOBP allows us to illustrate the changes in plateau flatness,
range, and biological effectiveness – a “range mod” miti-
gates all three of these effects. With this method, both PSD
number and patient set up time potentially decrease. All
work presented was conducted in compliance with institu-
tional norms and doses delivered and volumes treated were
within the standard of care for the case described.
The “range mod” technique will be illustrated with
evaluation of a retreatment patient plan treated at our
center with PBT. This patient had recurrent ependy-
moma in the posterior fossa. Treatment plans were con-
structed using 3DCRT, IMRT, NRMPBT, and RMPBT
techniques. The range modulation plan employed end of
range modification of 3 mm, thus avoiding completetransmission through any OAR. While not the case in
the given example, our policy as noted above for plans
using a single beam is to employ three separate fields,
each with a unique range. In the plans shown, two
range-modulated fields per beam angle were used.
Xio 6.0 treatment planning software (Elekta AB,
Sweden) was used for all cases presented for PBT plan-
ning. Active scanning [17,18] as described previously
was employed for the delivery of the spread out Bragg
peaks (SOBPs) using apertures and compensators manu-
factured by IU Health Cyclotron Operations (IUCO).
Our uniform active scanning process requires the use of
apertures to shape the beam edge and compensators to
shape the beam end via direct range compensation, as a
sum these pieces of equipment are called patient specific
devices (PSDs). Aperture devices were machined out of
medical grade brass while compensators were machined
from medical grade Lucite using standard procedures;
U.S. Food and Drug Administration (FDA) requisite
quality assurance was performed. All beam outputs and
devices were checked for accuracy before treatment de-
livery per routine. At our center, each treatment posi-
tion’s verification images are reviewed by a physician for
every fraction in real time either at the gantry or via re-
mote viewing monitor prior to delivering beam.
The DICOM RT data set from the patient’s plan com-
puted on XiO was recovered and imported in the Eclipse
Figure 5 Comparison of the DVH’s for several OAR’s between the NRMPBT and the RMPBT plans shown in Figures 3 and 4
respecitively. In every case the RMPBT plan treats less volume of the OAR’s shown.
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parison use. All photon plans were constructed within
Eclipse 10. The deployed plan was compared to chart
data prior to de-identification in order to confirm the
correct recovery of the data and then doses to all con-
toured structures were converted into percentage format
for comparison.
The patient had been previously treated to 54 Gy via
coplanar IMRT and relapsed in field. This patient re-
ceived RMPBT at our center in order to avoid OARs ap-
proximately two years ago and is currently doing well
without evidence of radiation damage or other local
toxicity.
Results and discussion
Multiple beam plans were generated as primary treat-
ment for this patient using NRMPBT (Figure 3), RMBPT
(Figure 4), and a comparison of DVH’s for the NRMPBT
and RMPBT plans (Figure 5) are shown. Additionally,
the actual retreatment plan is shown in order to illus-
trate how RMPBT is used in this special context and is
labeled RMPBTrt (Figure 6). It varies from the optimal
RMPBT plan in that a vertex field is used so as to pulldose off the skin and minimize the volume of retreated
tissue outside of the PTV. Table 1 outlines the dosimet-
ric comparison of the plans.
All planning modalities produced plans that cover the
PTV. The RMPBT method treats less total brain than
the NRMPBT method given the fact that the beams are
not extended to cover the entirety of the brainstem in
an effort to avoid ending the beam in the brainstem.
When looking at the OAR doses, the difference in plans
is pronounced due to this difference. Data exist that sug-
gest doses over 10 Gy are sufficient to ultimately cause
hypothalamic dysfunction [19]. In the NRMPBT plan,
the average dose is lower, but the peak dose posteriorly
is close to the full prescription dose due to the goal of
treating through the full brainstem. Only in the RMPBT
plan is hypothalamic dose absent completely. This trend
continues for the doses to left and right cochleae, the
temporal lobes, the pituitary, and the brainstem itself.
These data are summarized in Table 1.
As a formal retreatment plan, behind the numbers in
the RMPBTrt plan is the concept of treating the previ-
ously treated tissue to the lowest sum doses possible.
This was achieved by minimizing dose overlap issues
Figure 6 The actual plan delivered using RMPBTrt (as part of retreatment). Vertex beams are used to minimize dose summation with the
prior coplanar IMRT plan this patient received. DVH colors are the same as used in Figure 3.
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retreatment proton plan (shown) via vertex beam usage.
The through brainstem approach or NRMPBT plan, had
a vertex field been employed, treats a much larger vol-
ume of hippocampus and temporal lobe, making its use
problematic in the retreatment context.
Even with the RMPBTrt plan’s beam arrangement used
to minimize overlap with prior dose, very significant
dosimetric saving occurred for the cochleae, the hypo-
thalamus, and the brainstem relative to the NRMPBT
plan. The hippocampal dose, despite the vertex field,
remained well below the mean dose seen by the other
methods.
The value of RMPBT is one of significantly increased pa-
tient safety by the direct reduction of treated tissue in a
fashion otherwise impossible even for traditional proton
therapy because it allows the safe termination of a proton
beam or set of beams in an OAR. The technique can be
adapted to use in pencil beam planning as well and may
prove to be even more critical in that arena as beam edge
dosimetry will likely need to become modulated as well.
In each case the number of PSD sets used was decreased
or kept the same. We hypothesize that time in the room
and complexity was decreased in every range modulated
patient scenario relative to electing another angle from
which to treat. Range modulation was simple to deliver inthe treatment rooms. Finally, as a result of fewer net patient
positions being used, fewer verifications films are needed
and patient exposure to radiation was decreased.
There are four main advantages to range modulation,
or smearing of the distal range of a proton beam, com-
pared to traditional multiple beam proton therapy:
1. Better tissue sparing is achieved via a more
aggressive use of distal blocking.
2. Theoretical time-savings in the treatment room as
fewer beam angles are needs. This could allow the
avoidance of anesthesia in some cases. It also de-
creases the need to wait for the physicians required
to review position films (every field is reviewed every
day in our center prior to beam delivery), improving
throughput.
3. Less image guidance imaging is used as only the first
of a range modified series of beams required image
guidance (orthogonal image verification).
4. No new PSD sets have to be manufactured which
saves time for the machine shop construction and
the cost of the materials and labor involved.
Range modulation as a methodology is not able to
solve all problems and can introduce new problems into
a plan. There is still entry dose overlap, it adds to the
Table 1 Dosimetric comparison of three plans
CTV PTV Brainstem Left cochlea Right cochlea Left temporal lobe Right temporal lobe Hypothalamus Pituitary Left hippocampus Right hippocampus Brain
NRMPBT Min 90.1 88.7 29.4 15.4 4.7 0 0 0 0 0 0 0
Max 108.1 109.4 103.6 49.9 25.6 102.8 100 96.7 1.2 65.8 57.8 108.5
Mean 100.4 100.1 97.9 30.2 11.6 2.2 1.5 13.8 0.2 4.4 4.1 14.4
RMPBT Min 79.9 63.2 0 3.9 0 0 0 0 0 0 0 0
Max 110.1 110.1 105.8 29.2 7.4 97.9 99.1 0 0 58.8 46.6 110.1
Mean 100.7 100.3 50.1 12.9 1.9 0.9 0.6 0 0 0.8 1.1 12.4
RMPBTrt Min 55.5 45.6 0 8.1 4.4 0 0 0 0 0 0 0
Max 100 100 96.7 27.7 15.2 94.8 92.5 0 0 81 70.3 100
Mean 94.5 93.6 42.4 16.9 8.2 4.3 2.6 0 0 11.5 8.7 20.7
















Table 2 Informal range modulation guidelines employed in our clinic
Clinical situation Approach used Example
Single beam being employed for more than a
few fractions.
Three ranges rather than two are used. 1. Full posterior fossa boost with full
cochlear sparing.
2. Boost for germinoma after whole
ventricular radiation often via a
posterior beam.
Three or more main angles are being used
and the patient is awake meaing six possible
fields may need to be delivered.
One of two ranges for each beam angle is
treated per day with care to avoid coincidental
beam ends. Ranges alternate each day.
1. Brain tumors.
2. Pelvic tumors.
3. Spine tumors in some cases.
Base of skull tumors.
The patient has had prior radiation. We will sometimes use three ranges rather than
two when super critical structures are involved.
1. Ependymoma retreatment with the
brainstem.
2. Salvage glioma cases with beams
ending in eloquent brain.
3. Retreatment patients with a distant
history of radiation necrosis with new
cancer in similar locations.
Two or more beams end in the same point
or points.
Beams are split into range mod pairs and care is
used to look at each end point set for each day
to avoid overlaps.
1. Fourth ventricular ependymoma.
2. Vertex beams use can hide this issue
and great care is used in plan review to
look for “in corner” doses.
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and if too few beams are used skin tolerance can be an
issue. Beam angle variation also can be quite valuable to
make plans more robust as target and other tissue vol-
umes change during treatment. This is important in ana-
tomical regions containing tissue/air/bone such as the
sinuses and hilar regions. This method is a new way of
employing the primary principle of radiation safety of
“as low as reasonably achievable,” more commonly
known by the acronym ALARA, in treatment. It is cost-
effective because no new PSD sets need to be con-
structed and the patient beam angle does not change in
the room taking time and requiring set-up imaging for
position verification. The presentation of this method is
obviously limited by the presentation of only one case,
but the idea has translated in our clinic to spinal cord
cases, craniopharyngiomas, optic pathway tumors, base
of skull tumors, and pelvic tumors. Careful evaluation of
the method will demonstrate that the method succeeds
by moderately smearing out the sharpness of the end of
the SOBP. This modest compromise allows safe stop-
page of proton beams within critical structures such as
the brainstem as shown. Ultimately it will be up to the
treating physician to balance the need for safety against
distal blocking goals regarding whether a biologic hot
spot in an OAR in a given plan is acceptable.
The method presented in this paper confronts a clin-
ical problem inherent in charged particle therapy – the
safe and effective management of the increasing RBE at
the end of particle beams. In all forms of past, present,
and future of charged particle therapy, the use of thismethod or an analogous approach will be of use to the
clinician when there is an RBE increase at the end of the
beam being used. One could even expand this idea to
any non-linearity found in RBE in beams as scanned
beams allow physicians to compensate for these issues.
Our future particle therapy treatment planning will likely
also be RBE focused rather than solely energy focused.
Table 2 summarizes the method’s usage in our clinic and
represents general guidelines.
Conclusions
This present study illustrates a novel method that miti-
gates the increased RBE at the end of the SOBP in pro-
ton treatment planning. It may not be applicable in all
situations and decreases the sharpness of the dose fall-
off at the end of the SOBP as a result. It has proven
practical to design and implement in our clinic. It is
most often used in plans using multiple beams. The
method represents treatment planning that reflects not
only thinking in terms of traditional energy dose (Gy)
but also in terms of biologic dose (RBE).
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